Inside EPA | Changes to EPA Priorities Due to COVID-19 May Persist after Pandemic

Elise Paeffgen comments on the medical waste industry’s planned response to increased volumes of COVID-19 waste.

Whatever the results of this presidential election, or any presidential transition, most government workers will continue to do the same work in the same way. In this article, Kevin Minoli draws upon his 18 years at the U.S. Environmental Protection Agency and takes a look at the COVID-19-related work of the EPA Office of Pesticide Programs as an example of an agency office that will continue to deliver results regardless of who wins on Nov. 3, 2020.

Our Environment, Land Use & Natural Resources Group explains the implications of the Environmental Protection Agency’s decision to end its temporary policy to exercise enforcement discretion for noncompliance of routine monitoring and reporting during the COVID-19 pandemic.

Whether your products are used for medical purposes or used in homes and offices, our Food, Drug & Device/FDA and Environment, Land Use & Natural Resources teams highlight the key regulatory requirements that apply, what has changed, and what the FDA and EPA will be watching out for when products are marketed for use in the evolving coronavirus (COVID-19) pandemic. 

Doug Arnold comments on the U.S. Environmental Protection Agency’s interim guidance on reducing or suspending certain cleanup work at Superfund sites due to COVID-19.